Nozomi Kuse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nozomi Kuse has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Masafumi Takiguchi
Division of International Collaboration Research and Tokyo Laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University , 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811
8 shared publications Tomohiro Akahoshi
Division of International Collaboration Research and Tokyo Joint Laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto/Tokyo, Japan
4 shared publicationsHiroyuki Gatanaga
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
2 shared publicationsShinichi Oka
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan
2 shared publications- Shinichi Oka
Japan Institute for Health Security, Tokyo 162-8655, Japan
2 shared publications - Takayuki Chikata
Division of International Collaboration Research and Tokyo Laboratory, Joint Research Center for Human Retrovirus Infection, Kumamoto University , 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811
2 shared publications
Latest Publications
- Open Access
- 6 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Molecular basis for selection and inhibition of HIV-1 escape virus by T cells and KIR2DL2+NK cells
NK cells and CD8+ T cells both contribute to HIV-1 control. These cells not only suppress HIV-1 replication, but also select HIV-1 escape mutant viruses. Most viruses bearing T cell escape mutations are expected to remain susceptible to NK cell suppression, but their inhibition by NK cells is unclear. We investigated the role of HIV-1-specific CD8+ T cells and NK cells recognizing superimposed Pol peptides in selection and control of HIV-1 mutant virus. KIR2DL2+NK cells have an enhanced ability to recognize HIV-1-infected cells after selection of Pol mutant virus by PolIY11-specific HLA-C*12:02-restricted T cells. Mass spectrometry-based immunopeptidome profiling of HIV-1-infected cells and analysis of crystal structures of TCR- and KIR2DL2-HLA-C*12:02-peptide complexes demonstrate the molecular basis for selection and recognition of the escape mutant epitope by TCR and KIR2DL2. The present study elucidates the mechanism for selection and inhibition of an HIV-1 escape virus by T cells and NK cells.
- 6 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessMolecular basis for selection and inhibition of HIV-1 escape virus by T cells and KIR2DL2+NK cells
NK cells and CD8+ T cells both contribute to HIV-1 control. These cells not only suppress HIV-1 replication, but also select HIV-1 escape mutant viruses. Most viruses bearing T cell escape mutations are expected to remain susceptible to NK cell suppression, but their inhibition by NK cells is unclear. We investigated the role of HIV-1-specific CD8+ T cells and NK cells recognizing superimposed Pol peptides in selection and control of HIV-1 mutant virus. KIR2DL2+NK cells have an enhanced ability to recognize HIV-1-infected cells after selection of Pol mutant virus by PolIY11-specific HLA-C*12:02-restricted T cells. Mass spectrometry-based immunopeptidome profiling of HIV-1-infected cells and analysis of crystal structures of TCR- and KIR2DL2-HLA-C*12:02-peptide complexes demonstrate the molecular basis for selection and recognition of the escape mutant epitope by TCR and KIR2DL2. The present study elucidates the mechanism for selection and inhibition of an HIV-1 escape virus by T cells and NK cells.
- Open Access
- 4 March 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (3) , e0250724
Virus-host immune interaction in asymptomatic HTLV-1 carriers
Human T-cell leukemia virus type 1 (HTLV-1) induces chronic long-term latent infection that can cause fatal diseases, including adult T-cell leukemia. HTLV-1 production is poor and undetectable during the asymptomatic phase of infection. Virus-host immune interaction in latent infection has not been fully determined. In the present study, virus-specific antibody and T-cell responses in asymptomatic HTLV-1 carriers ( n = 77) were investigated. Neutralizing antibody responses were significantly higher in individuals with higher anti-Env SU (gp46) antibody levels and positively correlated with proviral loads. Overnight ex vivo culture of peripheral blood mononuclear cells resulted in detectable HTLV-1 Gag antigen (p19) expression in CD4 + T cells and interferon-γ (IFN-γ) induction in CD8 + T cells. Frequencies of these p19-expressing CD4 + T cells and non-specific IFN-γ-induced CD8 + T cells were positively correlated with proviral loads, respectively. Tax-specific CD8 + T-cell frequencies were not associated with proviral loads but inversely correlated with the ratios of p19-expressing CD4 + T-cell frequencies to proviral loads, implying the involvement of Tax-specific CD8 + T cells in the control of HTLV-1 replication. These results provide insights into the elucidation of the virus-host immune interaction in latent HTLV-1 infection. IMPORTANCE: Human T-cell leukemia virus type 1 (HTLV-1) can cause fatal diseases, including adult T-cell leukemia in humans after long-term asymptomatic infection. In asymptomatic HTLV-1 carriers, substantial proviruses are detectable in lymphocytes, and the association of a higher proviral load with a higher risk of disease progression has been observed. However, viral replication is controlled and HTLV-1 production is poor in asymptomatic carriers. Virus-host immune interaction during latent infection has not been fully determined. In the present study, virus-specific antibody and T-cell responses in asymptomatic HTLV-1 carriers were investigated. Neutralizing antibody responses were positively correlated with proviral loads. Tax-specific CD8 + T-cell frequencies were not associated with proviral loads but inversely correlated with the ratios of p19-expressing CD4 + T-cell frequencies to proviral loads, supporting the notion that Tax-specific CD8 + T-cell responses play an important role in the control of HTLV-1 replication. These results provide insights into the mechanism of virus-host immune interaction in latent HTLV-1 infection.
- 4 March 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (3) , e0250724
Open AccessVirus-host immune interaction in asymptomatic HTLV-1 carriers
Human T-cell leukemia virus type 1 (HTLV-1) induces chronic long-term latent infection that can cause fatal diseases, including adult T-cell leukemia. HTLV-1 production is poor and undetectable during the asymptomatic phase of infection. Virus-host immune interaction in latent infection has not been fully determined. In the present study, virus-specific antibody and T-cell responses in asymptomatic HTLV-1 carriers ( n = 77) were investigated. Neutralizing antibody responses were significantly higher in individuals with higher anti-Env SU (gp46) antibody levels and positively correlated with proviral loads. Overnight ex vivo culture of peripheral blood mononuclear cells resulted in detectable HTLV-1 Gag antigen (p19) expression in CD4 + T cells and interferon-γ (IFN-γ) induction in CD8 + T cells. Frequencies of these p19-expressing CD4 + T cells and non-specific IFN-γ-induced CD8 + T cells were positively correlated with proviral loads, respectively. Tax-specific CD8 + T-cell frequencies were not associated with proviral loads but inversely correlated with the ratios of p19-expressing CD4 + T-cell frequencies to proviral loads, implying the involvement of Tax-specific CD8 + T cells in the control of HTLV-1 replication. These results provide insights into the elucidation of the virus-host immune interaction in latent HTLV-1 infection. IMPORTANCE: Human T-cell leukemia virus type 1 (HTLV-1) can cause fatal diseases, including adult T-cell leukemia in humans after long-term asymptomatic infection. In asymptomatic HTLV-1 carriers, substantial proviruses are detectable in lymphocytes, and the association of a higher proviral load with a higher risk of disease progression has been observed. However, viral replication is controlled and HTLV-1 production is poor in asymptomatic carriers. Virus-host immune interaction during latent infection has not been fully determined. In the present study, virus-specific antibody and T-cell responses in asymptomatic HTLV-1 carriers were investigated. Neutralizing antibody responses were positively correlated with proviral loads. Tax-specific CD8 + T-cell frequencies were not associated with proviral loads but inversely correlated with the ratios of p19-expressing CD4 + T-cell frequencies to proviral loads, supporting the notion that Tax-specific CD8 + T-cell responses play an important role in the control of HTLV-1 replication. These results provide insights into the mechanism of virus-host immune interaction in latent HTLV-1 infection.
- 23 July 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (7) , e0079124
Recognition of HIV-1-infected fibrocytes lacking Nef-mediated HLA-B downregulation by HIV-1-specific T cells
Fibrocytes were reported to be host cells for HIV-1, but the immunological recognition of HIV-1-infected fibrocytes has not been studied. Here, we investigated the recognition of HIV-1-infected fibrocytes by HIV-1-specific CD8 + T cells. CD8 + T cells specific for five HIV-1 epitopes (HLA-A*24:02-restricted, HLA-B*52:01-restricted, and HLA-C*12:02-restricted epitopes) produced IFN-γ and expressed CD107a after coculture with HIV-1-infected fibrocytes. HIV-1-infected fibrocytes were effectively killed by HIV-1-specific CD8 + T cells. Although it is well known that HIV-1 Nef-mediated downregulation of HLA-A and HLA-B critically affects the T cell recognition of HIV-1-infected CD4 + T cells and HIV-1-infected macrophages, Nef downregulated HLA-A, but not HLA-B, in HIV-1-infected fibrocytes. These findings suggested that HIV-1-specific CD8 + T cells could recognize HIV-1-infected fibrocytes more strongly than HIV-1-infected CD4 + T cells or HIV-1-infected macrophages. HIV-1-infected fibrocytes were also recognized by HIV-1-specific HLA-DR-restricted T cells, indicating that HIV-1-infected fibrocytes can present HIV-1 epitopes to helper T cells. Collectively, these findings suggest that fibrocytes have an important role as antigen-presenting cells during HIV-1 infection. The present study demonstrates effective recognition of HIV-1-infected fibrocytes by HIV-1-specific T cells and suggests possible roles of fibrocytes in the induction and maintenance of HIV-1-specific T cells. IMPORTANCE: Fibrocytes were identified as unique hematopoietic cells with the features of both macrophages and fibroblasts and were demonstrated to be host cells for HIV-1. However, T cell recognition of HIV-1-infected fibrocytes has not been studied. We investigated the recognition of HIV-1-infected fibrocytes by HIV-1-specific T cells. HIV-1-infected fibrocytes were effectively recognized and killed by CD8 + T cells specific for HIV-1 epitopes presented by HLA-A, HLA-B, or HLA-C and were recognized by HIV-1-specific HLA-DR-restricted CD4 + T cells. HIV-1 Nef-mediated downregulation of HLA-A and HLA-B was found in HIV-1-infected CD4 + T cells, whereas Nef did not downregulate HLA-B in HIV-1-infected fibrocytes. These results suggest that HIV-1-specific CD8 + T cells recognize HIV-1-infected fibrocytes more strongly than HIV-1-infected CD4 + T cells. The present study suggests the importance of fibrocytes in the induction and maintenance of HIV-1-specific T cells.
- 23 July 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (7) , e0079124
Recognition of HIV-1-infected fibrocytes lacking Nef-mediated HLA-B downregulation by HIV-1-specific T cells
Fibrocytes were reported to be host cells for HIV-1, but the immunological recognition of HIV-1-infected fibrocytes has not been studied. Here, we investigated the recognition of HIV-1-infected fibrocytes by HIV-1-specific CD8 + T cells. CD8 + T cells specific for five HIV-1 epitopes (HLA-A*24:02-restricted, HLA-B*52:01-restricted, and HLA-C*12:02-restricted epitopes) produced IFN-γ and expressed CD107a after coculture with HIV-1-infected fibrocytes. HIV-1-infected fibrocytes were effectively killed by HIV-1-specific CD8 + T cells. Although it is well known that HIV-1 Nef-mediated downregulation of HLA-A and HLA-B critically affects the T cell recognition of HIV-1-infected CD4 + T cells and HIV-1-infected macrophages, Nef downregulated HLA-A, but not HLA-B, in HIV-1-infected fibrocytes. These findings suggested that HIV-1-specific CD8 + T cells could recognize HIV-1-infected fibrocytes more strongly than HIV-1-infected CD4 + T cells or HIV-1-infected macrophages. HIV-1-infected fibrocytes were also recognized by HIV-1-specific HLA-DR-restricted T cells, indicating that HIV-1-infected fibrocytes can present HIV-1 epitopes to helper T cells. Collectively, these findings suggest that fibrocytes have an important role as antigen-presenting cells during HIV-1 infection. The present study demonstrates effective recognition of HIV-1-infected fibrocytes by HIV-1-specific T cells and suggests possible roles of fibrocytes in the induction and maintenance of HIV-1-specific T cells. IMPORTANCE: Fibrocytes were identified as unique hematopoietic cells with the features of both macrophages and fibroblasts and were demonstrated to be host cells for HIV-1. However, T cell recognition of HIV-1-infected fibrocytes has not been studied. We investigated the recognition of HIV-1-infected fibrocytes by HIV-1-specific T cells. HIV-1-infected fibrocytes were effectively recognized and killed by CD8 + T cells specific for HIV-1 epitopes presented by HLA-A, HLA-B, or HLA-C and were recognized by HIV-1-specific HLA-DR-restricted CD4 + T cells. HIV-1 Nef-mediated downregulation of HLA-A and HLA-B was found in HIV-1-infected CD4 + T cells, whereas Nef did not downregulate HLA-B in HIV-1-infected fibrocytes. These results suggest that HIV-1-specific CD8 + T cells recognize HIV-1-infected fibrocytes more strongly than HIV-1-infected CD4 + T cells. The present study suggests the importance of fibrocytes in the induction and maintenance of HIV-1-specific T cells.
- Open Access
- 30 November 2023
- Published by American Society for Microbiology in Journal of Virology
- Vol. 97 (11) , e0102423
Epitope-dependent effect of long-term cART on maintenance and recovery of HIV-1-specific CD8 + T cells
The frequency of HIV-1-specific T cells is reduced and their functional ability remains impaired in people living with HIV-1 (PLWH) under combined antiretroviral therapy (cART). However, no studies have yet reported on T-cell responses to large numbers of well-characterized HIV-1 epitopes before and under cART within the same individuals. Therefore, how cART affects the maintenance of HIV-1-specific CD8 + T cells and which HIV-1-specific CD8 + T cells would be useful for curative treatment remain unclear. We investigated T-cell responses to 63 HIV-1 epitopes at pre-cART and under cART in 90 PLWH who received long-term cART. The frequency of T-cell responses to HIV-1 epitopes under long-term cART varied from 0% to 100%, indicating an epitope-dependent effect of long-term cART on HIV-1-specific CD8 + T cells. The magnitude of the responses under cART was 26.2% of that at pre-cART. The frequency of T-cell responses to protective epitopes under cART was higher than that to non-protective ones. T-cell responses to HIV-1 epitopes were detected at pre-cART in most non-AIDS HIV patients, whereas they were not detectable at pre-cART in half of the AIDS patients. Long-term cART enhanced the ability of HIV-1-specific T cells to proliferate in vitro in non-AIDS HIV patients, while it restored this ability of the T cells in AIDS patients. This study demonstrated that CD8 + T cells specific for large numbers of HIV-1 epitopes were maintained in an epitope-dependent fashion under long-term cART and implied that some HIV-1-specific T cells are still candidates as effector cells for curative treatment. IMPORTANCE: HIV-1-specific CD8 + T cells are anticipated to become effector cells for curative treatment using the “shock and kill” approach in people living with HIV-1 (PLWH) under combined antiretroviral therapy (cART). Previous studies demonstrated that the frequency of HIV-1-specific CD8 + T cells is reduced under cART and their functional ability remains impaired. These studies analyzed T-cell responses to a small number of HIV-1 epitopes or overlapping HIV-1 peptides. Therefore, the features of CD8 + T cells specific for HIV-1 epitopes under cART remain only partially clarified. Here, we analyzed CD8 + T cells specific for 63 well-characterized epitopes in 90 PLWH. We demonstrated that CD8 + T cells specific for large numbers of HIV-1 epitopes were maintained in an epitope-dependent fashion under long-term cART and that long-term cART enhanced or restored the ability of HIV-1-specific T cells to proliferate in vitro . This study implies that some HIV-1-specific T cells would be useful as effector cells for curative treatment.
- 30 November 2023
- Published by American Society for Microbiology in Journal of Virology
- Vol. 97 (11) , e0102423
Open AccessEpitope-dependent effect of long-term cART on maintenance and recovery of HIV-1-specific CD8 + T cells
The frequency of HIV-1-specific T cells is reduced and their functional ability remains impaired in people living with HIV-1 (PLWH) under combined antiretroviral therapy (cART). However, no studies have yet reported on T-cell responses to large numbers of well-characterized HIV-1 epitopes before and under cART within the same individuals. Therefore, how cART affects the maintenance of HIV-1-specific CD8 + T cells and which HIV-1-specific CD8 + T cells would be useful for curative treatment remain unclear. We investigated T-cell responses to 63 HIV-1 epitopes at pre-cART and under cART in 90 PLWH who received long-term cART. The frequency of T-cell responses to HIV-1 epitopes under long-term cART varied from 0% to 100%, indicating an epitope-dependent effect of long-term cART on HIV-1-specific CD8 + T cells. The magnitude of the responses under cART was 26.2% of that at pre-cART. The frequency of T-cell responses to protective epitopes under cART was higher than that to non-protective ones. T-cell responses to HIV-1 epitopes were detected at pre-cART in most non-AIDS HIV patients, whereas they were not detectable at pre-cART in half of the AIDS patients. Long-term cART enhanced the ability of HIV-1-specific T cells to proliferate in vitro in non-AIDS HIV patients, while it restored this ability of the T cells in AIDS patients. This study demonstrated that CD8 + T cells specific for large numbers of HIV-1 epitopes were maintained in an epitope-dependent fashion under long-term cART and implied that some HIV-1-specific T cells are still candidates as effector cells for curative treatment. IMPORTANCE: HIV-1-specific CD8 + T cells are anticipated to become effector cells for curative treatment using the “shock and kill” approach in people living with HIV-1 (PLWH) under combined antiretroviral therapy (cART). Previous studies demonstrated that the frequency of HIV-1-specific CD8 + T cells is reduced under cART and their functional ability remains impaired. These studies analyzed T-cell responses to a small number of HIV-1 epitopes or overlapping HIV-1 peptides. Therefore, the features of CD8 + T cells specific for HIV-1 epitopes under cART remain only partially clarified. Here, we analyzed CD8 + T cells specific for 63 well-characterized epitopes in 90 PLWH. We demonstrated that CD8 + T cells specific for large numbers of HIV-1 epitopes were maintained in an epitope-dependent fashion under long-term cART and that long-term cART enhanced or restored the ability of HIV-1-specific T cells to proliferate in vitro . This study implies that some HIV-1-specific T cells would be useful as effector cells for curative treatment.
- Open Access
- 26 July 2021
- Published by American Society for Microbiology in Journal of Virology
- Vol. 95 (16) , e0069921
STING Ligand-Mediated Priming of Functional CD8+T Cells Specific for HIV-1-Protective Epitopes from Naive T Cells
The current “shock-and-kill” therapeutic strategy for HIV cure has been directed toward eliminating latent viral reservoirs by reactivation of latent reservoirs with latency-reversing agents followed by eradication of these cells by immune-mediated responses. Although HIV-1-specific T cells are expected to eradicate viral reservoirs, the function of these T cells is reduced in HIV-1-infected individuals with long-term cART.
- 26 July 2021
- Published by American Society for Microbiology in Journal of Virology
- Vol. 95 (16) , e0069921
Open AccessSTING Ligand-Mediated Priming of Functional CD8+T Cells Specific for HIV-1-Protective Epitopes from Naive T Cells
The current “shock-and-kill” therapeutic strategy for HIV cure has been directed toward eliminating latent viral reservoirs by reactivation of latent reservoirs with latency-reversing agents followed by eradication of these cells by immune-mediated responses. Although HIV-1-specific T cells are expected to eradicate viral reservoirs, the function of these T cells is reduced in HIV-1-infected individuals with long-term cART.
- Open Access
- 1 April 2019
- Published by Elsevier in EBioMedicine
- Vol. 42, 109-119
Priming of HIV-1-specific CD8+ T cells with strong functional properties from naïve T cells
- 1 April 2019
- Published by Elsevier in EBioMedicine
- Vol. 42, 109-119
Open AccessPriming of HIV-1-specific CD8+ T cells with strong functional properties from naïve T cells
- Open Access
- 28 February 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (7)
The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells
Pathogen recognition receptor (PRR) agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. Using an original in vitro approach to prime naive precursors from unfractionated human peripheral blood mononuclear cells, we assessed the influence of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), a ligand for the stimulator of interferon genes (STING), on the induction of antigen-specific CD8 + T cells. We found that 2′3′-cGAMP and 3′3′-cGAMP were especially potent adjuvants in this system, driving the expansion and maturation of functionally replete antigen-specific CD8 + T cells via the induction of type I IFNs. The biological relevance of these findings was confirmed in vivo using two mouse models, in which 2′3′-cGAMP–adjuvanted vaccination elicited protective antitumor or antiviral CD8 + T cell responses. These results identify particular isoforms of cGAMP as effective adjuvants that may find utility in the development of novel immunotherapies and vaccines.
- 28 February 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (7)
Open AccessThe STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells
Pathogen recognition receptor (PRR) agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. Using an original in vitro approach to prime naive precursors from unfractionated human peripheral blood mononuclear cells, we assessed the influence of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), a ligand for the stimulator of interferon genes (STING), on the induction of antigen-specific CD8 + T cells. We found that 2′3′-cGAMP and 3′3′-cGAMP were especially potent adjuvants in this system, driving the expansion and maturation of functionally replete antigen-specific CD8 + T cells via the induction of type I IFNs. The biological relevance of these findings was confirmed in vivo using two mouse models, in which 2′3′-cGAMP–adjuvanted vaccination elicited protective antitumor or antiviral CD8 + T cell responses. These results identify particular isoforms of cGAMP as effective adjuvants that may find utility in the development of novel immunotherapies and vaccines.
- Open Access
- 3 July 2018
- Published by Springer Nature in Retrovirology
- Vol. 15 (1) , 1-14
CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication
Development of AIDS vaccines for effective prevention of circulating HIV-1 is required, but no trial has demonstrated definitive effects on the prevention. Several recent T-cell vaccine trials showed no protection against HIV-1 acquisition although the vaccines induced HIV-1-specific T-cell responses, suggesting that the vaccine-induced T cells have insufficient capacities to suppress HIV-1 replication and/or cross-recognize circulating HIV-1. Therefore, it is necessary to develop T-cell vaccines that elicit T cells recognizing shared protective epitopes with strong ability to suppress HIV-1. We recently designed T-cell mosaic vaccine immunogens tHIVconsvX composed of 6 conserved Gag and Pol regions and demonstrated that the T-cell responses to peptides derived from the vaccine immunogens were significantly associated with lower plasma viral load (pVL) and higher CD4+ T-cell count (CD4 count) in HIV-1-infected, treatment-naive Japanese individuals. However, it remains unknown T cells of which specificities have the ability to suppress HIV-1 replication. In the present study, we sought to identify more T cells specific for protective Gag epitopes in the vaccine immunogens, and analyze their abilities to suppress HIV-1 replication and recognize epitope variants in circulating HIV-1. We determined 17 optimal Gag epitopes and their HLA restriction, and found that T-cell responses to 9 were associated significantly with lower pVL and/or higher CD4 count. T-cells recognizing 5 of these Gag peptides remained associated with good clinical outcome in 221 HIV-1-infected individuals even when comparing responders and non-responders with the same restricting HLA alleles. Although it was known previously that T cells specific for 3 of these protective epitopes had strong abilities to suppress HIV-1 replication in vivo, here we demonstrated equivalent abilities for the 2 novel epitopes. Furthermore, T cells against all 5 Gag epitopes cross-recognized variants in majority of circulating HIV-1. We demonstrated that T cells specific for 5 Gag conserved epitopes in the tHIVconsvX have ability to suppress replication of circulating HIV-1 in HIV-1-infected individuals. Therefore, the tHIVconsvX vaccines have the right specificity to contribute to prevention of HIV-1 infection and eradication of latently infected cells following HIV-1 reactivation.
- 3 July 2018
- Published by Springer Nature in Retrovirology
- Vol. 15 (1) , 1-14
Open AccessCD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication
Development of AIDS vaccines for effective prevention of circulating HIV-1 is required, but no trial has demonstrated definitive effects on the prevention. Several recent T-cell vaccine trials showed no protection against HIV-1 acquisition although the vaccines induced HIV-1-specific T-cell responses, suggesting that the vaccine-induced T cells have insufficient capacities to suppress HIV-1 replication and/or cross-recognize circulating HIV-1. Therefore, it is necessary to develop T-cell vaccines that elicit T cells recognizing shared protective epitopes with strong ability to suppress HIV-1. We recently designed T-cell mosaic vaccine immunogens tHIVconsvX composed of 6 conserved Gag and Pol regions and demonstrated that the T-cell responses to peptides derived from the vaccine immunogens were significantly associated with lower plasma viral load (pVL) and higher CD4+ T-cell count (CD4 count) in HIV-1-infected, treatment-naive Japanese individuals. However, it remains unknown T cells of which specificities have the ability to suppress HIV-1 replication. In the present study, we sought to identify more T cells specific for protective Gag epitopes in the vaccine immunogens, and analyze their abilities to suppress HIV-1 replication and recognize epitope variants in circulating HIV-1. We determined 17 optimal Gag epitopes and their HLA restriction, and found that T-cell responses to 9 were associated significantly with lower pVL and/or higher CD4 count. T-cells recognizing 5 of these Gag peptides remained associated with good clinical outcome in 221 HIV-1-infected individuals even when comparing responders and non-responders with the same restricting HLA alleles. Although it was known previously that T cells specific for 3 of these protective epitopes had strong abilities to suppress HIV-1 replication in vivo, here we demonstrated equivalent abilities for the 2 novel epitopes. Furthermore, T cells against all 5 Gag epitopes cross-recognized variants in majority of circulating HIV-1. We demonstrated that T cells specific for 5 Gag conserved epitopes in the tHIVconsvX have ability to suppress replication of circulating HIV-1 in HIV-1-infected individuals. Therefore, the tHIVconsvX vaccines have the right specificity to contribute to prevention of HIV-1 infection and eradication of latently infected cells following HIV-1 reactivation.
- Open Access
- 1 March 2018
- Published by American Society for Microbiology in Journal of Virology
- Vol. 92 (5) , e01749-17
HLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E
HIV-1-specific cytotoxic T cells (CTLs) play an important role in the control of HIV-1 subtype B or C infection. However, the role of CTLs in HIV-1 subtype A/E infection still remains unclear. Here we investigated the association of HLA class I alleles with clinical outcomes in treatment-naive Vietnamese infected with subtype A/E virus. We found that HLA-C*12:02 was significantly associated with lower plasma viral loads (pVL) and higher CD4 counts and that the HLA-A*29:01-B*07:05-C*15:05 haplotype was significantly associated with higher pVL and lower CD4 counts than those for individuals without these respective genotypes. Nine Pol and three Nef mutations were associated with at least one HLA allele in the HLA-A*29:01-B*07:05-C*15:05 haplotype, with a strong negative correlation between the number of HLA-associated Pol mutations and CD4 count as well as a positive correlation with pVL for individuals with these HLA alleles. The results suggest that the accumulation of mutations selected by CTLs restricted by these HLA alleles affects HIV control. IMPORTANCE Most previous studies on HLA association with disease progression after HIV-1 infection have been performed on cohorts infected with HIV-1 subtypes B and C, whereas few such population-based studies have been reported for cohorts infected with the Asian subtype A/E virus. In this study, we analyzed the association of HLA class I alleles with clinical outcomes for 536 HIV-1 subtype A/E-infected Vietnamese individuals. We found that HLA-C*12:02 is protective, while the HLA haplotype HLA-A*29:01-B*07:05-C*15:05 is deleterious. The individuals with HIV-1 mutations associated with at least one of the HLA alleles in the deleterious HLA haplotype had higher plasma viral loads and lower CD4 counts than those of individuals without the mutations, suggesting that viral adaptation and escape from HLA-mediated immune control occurred. The present study identifies a protective allele and a deleterious haplotype for HIV-1 subtype A/E infection which are different from those identified for cohorts infected with HIV-1 subtypes B and C.
- 1 March 2018
- Published by American Society for Microbiology in Journal of Virology
- Vol. 92 (5) , e01749-17
Open AccessHLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E
HIV-1-specific cytotoxic T cells (CTLs) play an important role in the control of HIV-1 subtype B or C infection. However, the role of CTLs in HIV-1 subtype A/E infection still remains unclear. Here we investigated the association of HLA class I alleles with clinical outcomes in treatment-naive Vietnamese infected with subtype A/E virus. We found that HLA-C*12:02 was significantly associated with lower plasma viral loads (pVL) and higher CD4 counts and that the HLA-A*29:01-B*07:05-C*15:05 haplotype was significantly associated with higher pVL and lower CD4 counts than those for individuals without these respective genotypes. Nine Pol and three Nef mutations were associated with at least one HLA allele in the HLA-A*29:01-B*07:05-C*15:05 haplotype, with a strong negative correlation between the number of HLA-associated Pol mutations and CD4 count as well as a positive correlation with pVL for individuals with these HLA alleles. The results suggest that the accumulation of mutations selected by CTLs restricted by these HLA alleles affects HIV control. IMPORTANCE Most previous studies on HLA association with disease progression after HIV-1 infection have been performed on cohorts infected with HIV-1 subtypes B and C, whereas few such population-based studies have been reported for cohorts infected with the Asian subtype A/E virus. In this study, we analyzed the association of HLA class I alleles with clinical outcomes for 536 HIV-1 subtype A/E-infected Vietnamese individuals. We found that HLA-C*12:02 is protective, while the HLA haplotype HLA-A*29:01-B*07:05-C*15:05 is deleterious. The individuals with HIV-1 mutations associated with at least one of the HLA alleles in the deleterious HLA haplotype had higher plasma viral loads and lower CD4 counts than those of individuals without the mutations, suggesting that viral adaptation and escape from HLA-mediated immune control occurred. The present study identifies a protective allele and a deleterious haplotype for HIV-1 subtype A/E infection which are different from those identified for cohorts infected with HIV-1 subtypes B and C.